Targeting MAST1 using a well-tolerated small molecule kinase inhibitor lestaurtinib may be a method to abrogate the possible effects of steroids on tumor growth as treatment with lestaurtinib effectively re-sensitized tumors to cisplatin treatment while not interrupting the anti-inflammatory activity. Here, MAST1 is linked to neoplasm.